MREO

Mereo BioPharma Group plc (MREO) ESG Analysis Analysis (2026)

Invetso Score: 5.2/10 — Balanced · Last Updated: 2026-09-01

Environmental

No material environmental disclosures or controversies in the provided data.

Small balance sheet and minimal capital intensity suggest limited near-term environmental footprint.

Social

No material social disclosures or controversies in the provided data.

No recent news indicating labor, product safety, or customer-related issues.

Governance

Very low debt-to-equity and debt-to-assets ratios indicate conservative leverage.

High current and cash ratios suggest strong short-term liquidity.

Overall

Strong liquidity and low leverage support financial resilience.

Absence of ESG disclosures and ongoing losses keep the profile only moderate.

Overall Score

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Mereo BioPharma Group plc. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →